Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year. Net income was $915.7 million, or $3.52 per share, compared to $810.5 million, or $3.13 per share, last year. Adjusted EPS was $3.89. For the full year of 2023, CF product revenues are expected […]
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year. Net income was $915.7 million, or $3.52 per share, compared to $810.5 million, or $3.13 per share, last year. Adjusted EPS was $3.89. For the full year of 2023, CF product revenues are expected […]
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) reported product revenue of $2.49 billion for the second quarter of 2023, which was up 14% year-over-year.
Net income was $915.7 million, or $3.52 per share, compared to $810.5 million, or $3.13 per share, last year. Adjusted EPS was $3.89.
For the full year of 2023, CF product revenues are expected to range between $9.7-9.8 billion.
